Standout Papers

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck 2006 2026 2012 2019 3.6k
  1. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck (2006)
    James A. Bonner, Paul M. Harari et al. New England Journal of Medicine
  2. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer (2008)
    Jan B. Vermorken, Ricard Mesı́a et al. New England Journal of Medicine
  3. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy (2007)
    Jan B. Vermorken, José Trigo et al. Journal of Clinical Oncology
  4. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer (2023)
    Gerald W. Prager, Julien Taı̈eb et al. New England Journal of Medicine

Immediate Impact

3 by Nobel laureates 4 from Science/Nature 96 standout
Sub-graph 1 of 15

Citing Papers

Colorectal cancer
2024 Standout
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
2024 Standout
3 intermediate papers

Works of Nadia Amellal being referenced

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2023 Standout
Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.
2023
and 1 more

Author Peers

Author Last Decade Papers Cites
Nadia Amellal 5130 3975 4123 60 8.8k
Ricardo Hitt 3937 2868 3407 68 6.5k
Christopher U. Jones 3655 5101 4855 67 10.2k
K. Kian Ang 3005 3063 4754 74 8.8k
Didier Cupissol 4846 4338 2878 160 8.7k
Ranjan Sur 2895 2910 2555 68 6.3k
A. Dimitrios Colevas 3289 2030 2528 189 7.4k
N. Azarnia 3420 2702 1973 52 6.4k
Ihor Vynnychenko 4448 4232 1379 56 6.8k
Rita Axelrod 2419 2027 4227 50 6.4k
John F. Ensley 5529 4679 9711 123 13.9k

All Works

Loading papers...

Rankless by CCL
2026